ASCLETIS ANNOUNCES FIRST PARTICIPANTS WITH OBESITY OR OVERWEIGHT DOSED IN A U.S. 13-WEEK PHASE IIA STUDY OF SMALL MOLECULE ORAL GLP-1R AGONIST ASC30

Reuters · 6d ago

Please log in to view news